Advertisement
Screener

ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) Increase (Decrease) in Other Operating Assets and Liabilities, Net

2.8 / 5 stars · 68/120 Roast Me

ADAPTIVE BIOTECHNOLOGIES CORPORATION Increase (Decrease) in Other Operating Assets and Liabilities, Net

ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of $201.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2026-08-04

  • ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-06-30 was $103.00K.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-03-31 was $98.00K, a 1533.33% increase year-over-year.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-12-31 was -$137.00K.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-09-30 was $0.00.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in other operating assets and liabilities, net for fiscal 2025 was -$142.00K.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in other operating assets and liabilities, net for fiscal 2024 was -$27.00K, a 136.99% decline from fiscal 2023.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in other operating assets and liabilities, net for fiscal 2023 was $73.00K.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in other operating assets and liabilities, net for fiscal 2022 was -$169.00K, a 161.45% decline from fiscal 2021.
Period endIncrease (Decrease) in Other Operating Assets and Liabilities, Net 3 monthIncrease (Decrease) in Other Operating Assets and Liabilities, Net 6 monthIncrease (Decrease) in Other Operating Assets and Liabilities, Net 9 monthIncrease (Decrease) in Other Operating Assets and Liabilities, Net 12 month
2026-06-30$103.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$201.00K
10-Q · filed 2026-08-04
$64.00K
derived: sum of 3 quarters · filed 2026-08-04
$64.00K
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31$98.00K
10-Q · filed 2026-05-05
-$39.00K
derived: sum of 2 quarters · filed 2026-05-05
-$39.00K
derived: sum of 3 quarters · filed 2026-05-05
-$50.00K
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31-$137.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$137.00K
derived: sum of 2 quarters · filed 2026-02-26
-$148.00K
derived: sum of 3 quarters · filed 2026-08-04
-$142.00K
10-K · filed 2026-02-26
2025-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
-$11.00K
derived: sum of 2 quarters · filed 2026-08-04
-$5.00K
10-Q · filed 2025-11-05
-$10.00K
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30-$11.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
-$5.00K
10-Q · filed 2026-08-04
-$10.00K
derived: sum of 3 quarters · filed 2026-08-04
-$13.00K
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31$6.00K
10-Q · filed 2026-05-05
$1.00K
derived: sum of 2 quarters · filed 2026-05-05
-$2.00K
derived: sum of 3 quarters · filed 2026-05-05
-$23.00K
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31-$5.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$8.00K
derived: sum of 2 quarters · filed 2026-02-26
-$29.00K
derived: sum of 3 quarters · filed 2026-02-26
-$27.00K
10-K · filed 2026-02-26
2024-09-30-$3.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
-$24.00K
derived: sum of 2 quarters · filed 2025-11-05
-$22.00K
10-Q · filed 2025-11-05
-$25.00K
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30-$21.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05
-$19.00K
10-Q · filed 2025-08-05
-$22.00K
derived: sum of 3 quarters · filed 2026-02-26
$42.00K
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31$2.00K
10-Q · filed 2025-05-01
-$1.00K
derived: sum of 2 quarters · filed 2026-02-26
$63.00K
derived: sum of 3 quarters · filed 2026-02-26
$61.00K
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31-$3.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$61.00K
derived: sum of 2 quarters · filed 2026-02-26
$59.00K
derived: sum of 3 quarters · filed 2026-02-26
$73.00K
10-K · filed 2026-02-26
2023-09-30$64.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
$62.00K
derived: sum of 2 quarters · filed 2024-11-07
$76.00K
10-Q · filed 2024-11-07
$72.00K
derived: sum of 4 quarters · filed 2025-03-03
2023-06-30-$2.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01
$12.00K
10-Q · filed 2024-08-01
$8.00K
derived: sum of 3 quarters · filed 2025-03-03
-$60.00K
derived: sum of 4 quarters · filed 2025-03-03
2023-03-31$14.00K
10-Q · filed 2024-05-07
$10.00K
derived: sum of 2 quarters · filed 2025-03-03
-$58.00K
derived: sum of 3 quarters · filed 2025-03-03
2022-12-31-$4.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03
-$72.00K
derived: sum of 2 quarters · filed 2025-03-03
-$169.00K
10-K · filed 2025-03-03
2022-09-30-$68.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
-$165.00K
10-Q · filed 2023-11-09
2022-06-30-$97.00K
10-Q · filed 2023-08-02
2021-12-31$3.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
$155.00K
derived: sum of 2 quarters · filed 2024-02-29
$156.00K
derived: sum of 3 quarters · filed 2024-02-29
$275.00K
10-K · filed 2024-02-29
2021-09-30$152.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
$153.00K
derived: sum of 2 quarters · filed 2022-11-03
$272.00K
10-Q · filed 2022-11-03
$333.00K
derived: sum of 4 quarters · filed 2023-02-14
2021-06-30$1.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03
$120.00K
10-Q · filed 2022-08-03
$181.00K
derived: sum of 3 quarters · filed 2023-02-14
$181.00K
derived: sum of 4 quarters · filed 2023-02-14
2021-03-31$119.00K
10-Q · filed 2022-05-04
$180.00K
derived: sum of 2 quarters · filed 2023-02-14
$180.00K
derived: sum of 3 quarters · filed 2023-02-14
$180.00K
derived: sum of 4 quarters · filed 2023-02-14
2020-12-31$61.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14
$61.00K
derived: sum of 2 quarters · filed 2023-02-14
$61.00K
derived: sum of 3 quarters · filed 2023-02-14
$276.00K
10-K · filed 2023-02-14
2020-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03
$0.00
derived: sum of 2 quarters · filed 2021-11-03
$215.00K
10-Q · filed 2021-11-03
$275.00K
derived: sum of 4 quarters · filed 2022-02-15
2020-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04
$215.00K
10-Q · filed 2021-08-04
$275.00K
derived: sum of 3 quarters · filed 2022-02-15
$813.00K
derived: sum of 4 quarters · filed 2022-02-15
2020-03-31$215.00K
10-Q · filed 2021-05-05
$275.00K
derived: sum of 2 quarters · filed 2022-02-15
$813.00K
derived: sum of 3 quarters · filed 2022-02-15
2019-12-31$60.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15
$598.00K
derived: sum of 2 quarters · filed 2022-02-15
$597.00K
10-K · filed 2022-02-15
2019-09-30$538.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10
$537.00K
10-Q · filed 2020-11-10
2019-06-30-$1.00K
10-Q · filed 2020-08-10
2018-12-31-$24.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24
-$25.00K
derived: sum of 2 quarters · filed 2021-02-24
$182.00K
10-K · filed 2021-02-24
2018-09-30-$1.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
$206.00K
10-Q · filed 2019-11-12
2018-06-30$207.00K
10-Q · filed 2019-08-13
2017-12-31-$24.00K
10-K · filed 2020-02-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)United States$4.897B-6.51
CRISPR Therapeutics AG (CRSP)$5.390B-11.68
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Greenland Mines Ltd (GRML)United States$2.362B